Start here if you're new
what it is
Celanese makes specialty materials and industrial chemicals that end up in cars, electronics, food ingredients, paints, and factories.
how it gets paid
Last year Celanese made $9.5B in revenue.
why growth slowed
Revenue fell 7.1% last year. Celanese should report top- and bottom-line pressure when demand and spreads are soft.
what just happened
A typical quarter is on the order of ~$2.4B revenue (≈¼ of $9.5B FY)—not $7.3B as one quarter. EPS $0.67 vs ~$1.25 estimate in this feed.
At a glance
B+ balance sheet — decent shape, but not bulletproof
50/100 earnings predictability — expect surprises
10.7x trailing p/e — the market's not buying it — or you found a deal
0.4% dividend yield — cash in your pocket every quarter
5.0% return on capital — nothing to write home about
xvary composite: 56/100 — below average
What they do
Celanese makes specialty materials and industrial chemicals that end up in cars, electronics, food ingredients, paints, and factories.
Celanese wins by sitting in two hard-to-replace spots at once: Engineered Materials is 54% of sales, while Acetyl Chain is 46%, based on the company business summary. That mix matters because you get custom plastics on one side and chemical feedstocks on the other. If your customer designs Celanese material into a part, switching means requalifying the product, retesting performance, and risking downtime.
How they make money
$9.5B
annual revenue · revenue declined -7.1% last year
total revenue
$9.5B
7.1%
The products that matter
industrial chemicals and engineered materials
materials portfolio
$9.5B revenue · -7.1% last year
the snapshot data rolls the business up rather than breaking out each segment, so the number that matters is the full $9.5B revenue base — and it shrank 7.1%.
entire business
earnings power
EPS base
~$4.25 FY25 EPS est · ~10.7x forward P/E at $45.64
The ~$4.25 FY25 EPS est. in key numbers implies ~10.7x forward at $45.64. The glance strip’s ~10.7x trailing uses a different trailing EPS—same headline multiple, not the same denominator.
valuation hook
balance sheet constraint
debt load
$11.7B · 70% of capital
this is the quiet part loud: $11.7B in long-term debt matters as much as any product line because it limits how much bad demand you can afford.
the real swing factor
Key numbers
$11.7B
long-term debt
This is the number running the show. Your equity is about $5 billion, so the debt stack is more than twice the market value.
8.2%
operating margin
Operating margin → profit from the business before interest and taxes → at 8.2%, ops are still positive but thin for a debt-heavy chemicals name.
$4.25
2025 EPS est.
EPS → profit per share → so what: expected earnings are about half of 2024's $8.47, so the rebound story needs proof.
$72
18-month target
That target is 58% above $45.64, which tells you analysts see recovery upside if demand and margins stop sliding.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 25 / 100
- long-term debt $11.7B (70% of capital)
- net profit margin 8.5% — keeps 8 cents of every dollar in revenue
- return on equity 16% — $0.16 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in CE 3 years ago → it's now worth $3,930.
The index would have given you $14,770.
source: institutional data · total return
What just happened
missed estimates
Quarterly revenue near ~$2.4B (≈¼ of $9.5B FY)—not $7.3B as one quarter. EPS $0.67 vs ~$1.25 estimate.
Mix and comparison periods can move the sales line without fixing margins. Gross margin was 20.8%, and the last reported earnings surprise was -46.4%.
~$2.4B
Q revenue (approx.)
$0.67
eps
20.8%
gross margin
the number that mattered
The key number was the -46.4% earnings miss, because it says the recovery story is still arriving late.
-
celanese corporation should report top- and bottom-line declines in 2025.
-
we expect the global specialty materials and chemical company to deliver revenues around $9.6 billion, which would reflect a 7% vs. prior year decline.
-
meanwhile, we also project adjusted earnings to contract roughly 49%, to $4.25 per share.this is likely to be the result of a difficult operating environment characterized by continued weak demand in key regions, inventory challenges, and pressure in the company’s acetate tow and vinyls segments. management now anticipates a weaker-than-expected start to 2026 in the north american commodity chemicals sector, citing sluggish demand growth and heavy inventory overhang.
-
headwinds continue to face the industrial chemicals sector in the near-term.
-
the regulatory landscape is rapidly evolving as the u.s.environmental protection agency (epa) and european chemicals agency (echa) tighten controls on chemicals like perfluoralkyl and polyfluoroalkyl substances (pfas). in 2026, the echa plans pfas restriction across europe, while both the u.s. and mexico have initiated phased bans on pfas in consumer products.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is another demand slump in industrial chemicals while $11.7B of debt stays in place.
high
weak end-market demand
last year's revenue already fell 7.1%, and current quarter estimates call for another 9% drop from a year ago. If customers keep destocking, the pressure hits the whole $9.5B revenue base.
exposes the full business, not just one segment
high
balance sheet leverage
$11.7B in long-term debt equals 70% of capital. In plain English: if earnings weaken again, equity holders have less room for error than the market cap alone suggests.
capital structure limits flexibility
med
inventory and execution pressure
management has already pointed to inventory challenges and a weak start to 2026 in north american commodity chemicals. That usually means pricing and volumes are both less cooperative than they need to be.
shows up quickly in quarterly EPS
med
chemical regulation
PFAS rules are tightening in europe, and restrictions are expanding in north america. Even if Celanese adapts, compliance costs and product mix pressure are real operational risks.
regulatory change can pressure margins and product flexibility
if demand stays soft, the pain lands on a $9.5B revenue base while $11.7B in long-term debt reduces the margin for error.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
revenue declines need to stop getting worse
last year was -7.1%, and the next quarter estimate is -9% from a year ago. Stabilization is step one.
trend
watch estimate revisions, not just reported EPS
a stock can look cheap at 8.5x forward earnings right up until the forward number moves lower.
risk
debt needs to become less important to the story
$11.7B in long-term debt and 70% of capital is manageable only if operating performance stops slipping.
calendar
next earnings need to answer the north america question
management already flagged a weak start in commodity chemicals. You want to hear whether inventory is clearing or still clogging the channel.
Analyst rankings
short-term outlook
average
momentum score 3 — in human-speak, analysts see no clear short-term edge here.
risk profile
average
stability score 3 — typical on paper, though the leverage makes it feel less average in practice.
chart momentum
bottom 5%
technical score 5 — the lowest rating. The market has been treating every bounce like a selling opportunity.
earnings predictability
50 / 100
estimate quality is middling. You should expect revisions and occasional unpleasant surprises.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 180 buyers vs. 244 sellers in 3q2025. total institutional holdings: 0.1B shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$37
$106
$46
current price
$72
target midpoint · +58% from current · 3-5yr high: $90 (+95% · 19% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive